ChemoCentryx (CCXI) & Ocera Therapeutics (OCRX) Financial Review

Ocera Therapeutics (NASDAQ: OCRX) and ChemoCentryx (NASDAQ:CCXI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Earnings and Valuation

This table compares Ocera Therapeutics and ChemoCentryx’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ocera Therapeutics $610,000.00 77.79 -$26.89 million ($0.97) -1.85
ChemoCentryx $11.94 million 33.41 -$39.96 million ($0.60) -13.63

Ocera Therapeutics has higher earnings, but lower revenue than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Ocera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Ocera Therapeutics has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Ocera Therapeutics and ChemoCentryx, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocera Therapeutics 0 3 2 0 2.40
ChemoCentryx 0 1 1 0 2.50

Ocera Therapeutics presently has a consensus price target of $4.19, suggesting a potential upside of 133.94%. Given Ocera Therapeutics’ higher possible upside, analysts plainly believe Ocera Therapeutics is more favorable than ChemoCentryx.


This table compares Ocera Therapeutics and ChemoCentryx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocera Therapeutics N/A -383.51% -134.92%
ChemoCentryx N/A -67.57% -20.43%

Institutional and Insider Ownership

17.7% of Ocera Therapeutics shares are owned by institutional investors. Comparatively, 48.9% of ChemoCentryx shares are owned by institutional investors. 7.2% of Ocera Therapeutics shares are owned by insiders. Comparatively, 26.2% of ChemoCentryx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


ChemoCentryx beats Ocera Therapeutics on 7 of the 13 factors compared between the two stocks.

About Ocera Therapeutics

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

About ChemoCentryx

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Receive News & Ratings for Ocera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply